These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 27381025)

  • 1. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
    Vandiver JW; Vondracek TG
    Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study.
    Rizk E; Wilson AD; Murillo MU; Putney DR
    Ther Drug Monit; 2018 Feb; 40(1):151-155. PubMed ID: 29120972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.
    Mahmoud L; Zullo AR; McKaig D; Berard-Collins CM
    R I Med J (2013); 2016 Mar; 99(3):33-7. PubMed ID: 26929970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring.
    Frugé KS; Lee YR
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S90-7. PubMed ID: 26272899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
    Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
    Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
    Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
    Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
    Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
    Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
    Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
    Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.